Pulse Explorar nav.journalClub Debates Tendencias Investigadores Revistas

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Inicio Explorar nav.journalClub Tendencias

⌘+K

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer | Synapse

July 29, 2010Open Access

Ver artículo completo

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

Philip W. KantoffRutgers, The State University of New Jersey CHCelestia S. HiganoUniversité Paris-Sud NSNeal D. ShoreCarolina Urologic Research Center

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Sipuleucel-T, an autologous active cellular immunotherapy, has shown evidence of efficacy in reducing the risk of death among men with metastatic castration-resistant prostate cancer.

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Cite This Study

Kantoff et al. (Thu,) studied this question.

synapsesocial.com/papers/68f648ee33dca03d982ea4a3 https://doi.org/https://doi.org/10.1056/nejmoa1001294

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer.2006 · 492 citations
2Impact of Androgen Deprivation Therapy on Cardiovascular Disease and Diabetes2009 · 334 citations
3Metabolic changes during gonadotropin‐releasing hormone agonist therapy for prostate cancer2008 · 208 citations
4Cardiovascular Mortality and Duration of Androgen Deprivation for Locally Advanced Prostate Cancer: Analysis of RTOG 92-022008 · 200 citations
5Randomized Controlled Trial of Annual Zoledronic Acid to Prevent Gonadotropin-Releasing Hormone Agonist–Induced Bone Loss in Men With Prostate Cancer2007 · 327 citations